JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (38)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Witt, B. J.
Right arrow Articles by Kaye, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Witt, B. J.
Right arrow Articles by Kaye, A. D.
Related Collections
Right arrow Cardiovascular
Right arrow Monitoring (Cardiac)
Right arrow Pharmacology

Anesth Analg 2002;94:1427-1433
© 2002 International Anesthesia Research Society

CARDIOVASCULAR ANESTHESIA

An Analysis of Responses to Levosimendan in the Pulmonary Vascular Bed of the Cat

Bracken J. De Witt, MD PhD, Ikhlass N. Ibrahim, DVM, Erin Bayer, MD, Aaron M. Fields, BS, Todd A. Richards, BS, Ronald E. Banister, MD, and Alan D. Kaye, MD PhD

Departments of Anesthesiology and Pharmacology, Texas Tech University Health Sciences Center, Lubbock, Texas

Address correspondence and reprint requests to Alan D. Kaye, MD, PhD, Department of Anesthesiology, Texas Tech University Health Sciences Center, 3601 4th St., Rm. 1C-282, Lubbock, TX 79430. Address e-mail to aneadk{at}ttuhsc.edu

Calcium-sensitizing drugs, such as levosimendan, are a novel class of drug therapy for heart failure. We investigated the hypothesis that levosimendan is a pulmonary vasodepressor mediated through inhibition of phosphodiesterase, adenosine triphosphate (ATP)-dependent potassium channels, or both. We investigated responses to the calcium sensitizer levosimendan in the pulmonary vascular bed of the cat under conditions of controlled pulmonary blood flow and constant left atrial pressure when lobar arterial pressure was increased to a high steady level with the thromboxane A2 analog U-46619. Under increased-tone conditions, levosimendan caused dose-related decreases in lobar arterial pressure without altering systemic arterial and left atrial pressure. Responses to levosimendan were significantly attenuated, although not completely, after the administration of U-37883A, a vascular selective nonsulfonylurea ATP-sensitive K+-channel-blocking drug. Responses to levosimendan were not significantly different after the administration of the nitric oxide synthase inhibitor L-N5-(1-iminoethyl)-ornithine or the cyclooxygenase inhibitor sodium meclofenamate or when lung ventilation was interrupted. These data show that levosimendan has significant vasodilator activity in the pulmonary vascular bed of the cat. They also suggest that pulmonary vasodilator responses to levosimendan are partially dependent on activation of ATP-sensitive K+ channels and independent of the synthesis of nitric oxide, activation of cyclooxygenase enzyme, or changes in bronchomotor tone in the pulmonary vascular bed of the cat.

IMPLICATIONS: Calcium-sensitizing drugs, such as levosimendan, are a novel class of drug therapy for heart-failure treatment. The lung circulation affects both right- and left-sided heart failure. Levosimendan decreased lobar arterial pressure via a partial K+ATP (potassium channel sensitive to intracellular adenosine triphosphate levels)-dependent mechanism. These data suggest that, in addition to calcium-sensitizing activity, levosimendan decreases pulmonary resistance, which may also aid in the treatment of heart failure.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. N. Banfor, L. C. Preusser, T. J. Campbell, K. C. Marsh, J. S. Polakowski, G. A. Reinhart, B. F. Cox, and R. M. Fryer
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H238 - H248.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
F. R. Montes, D. Echeverri, L. Buitrago, I. Ramirez, J. C. Giraldo, J. D. Maldonado, and J. P. Umana
The Vasodilatory Effects of Levosimendan on the Human Internal Mammary Artery
Anesth. Analg., November 1, 2006; 103(5): 1094 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Usta, B. Eksert, I. Golbasi, Z. Bigat, and S. S. Ozdem
The role of potassium channels in the vasodilatory effect of levosimendan in human internal thoracic arteries.
Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 329 - 332.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
O. Yildiz, C. Nacitarhan, and M. Seyrek
Potassium Channels in the Vasodilating Action of Levosimendan on the Human Umbilical Artery
Reproductive Sciences, May 1, 2006; 13(4): 312 - 315.
[Abstract] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J.-P. Braun, M. Schneider, M. Kastrup, and J. Liu
Treatment of acute heart failure in an infant after cardiac surgery using levosimendan
Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 228 - 230.
[Abstract] [Full Text] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2002 by the International Anesthesia Research Society.